Holen Sie sich die Stockscreener-App
53.70
1.86%
-1.02
Vorhandelsmarkt:
51.90
-1.80
-3.35%
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Leerink Partnrs Has Strong Forecast for CRNX FY2024 Earnings - MarketBeat
Learn to Evaluate (CRNX) using the Charts - Stock Traders Daily
FY2024 Earnings Forecast for CRNX Issued By Lifesci Capital - Defense World
HC Wainwright Has Bearish Estimate for CRNX FY2024 Earnings - Defense World
Steven Cohen's Recent Transaction in Crinetics Pharmaceuticals Inc - GuruFocus.com
Crinetics Pharmaceuticals : 2024 Citi Global Healthcare Conference - Marketscreener.com
Crinetics Pharmaceuticals : 2024 Evercore 7th Annual HealthCONx Conference - Marketscreener.com
Crinetics Pharmaceuticals : 2024 Cantor Global Healthcare Conference - Marketscreener.com
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - The Manila Times
Crinetics Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | CRNX Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Crinetics Pharmaceuticals Inc - GuruFocus.com
HC Wainwright Has Pessimistic View of CRNX FY2024 Earnings - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week High Following Analyst Upgrade - Defense World
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline - GlobeNewswire
Crinetics Unveils Breakthrough Cancer Drug Platform, Reports Positive Phase 2 Trial Results | CRNX Stock News - StockTitan
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highl - GuruFocus.com
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Crinetics Pharmaceuticals to Showcase Pipeline Advancements - GlobeNewswire
Crinetics Pharmaceuticals, Inc. Announces Additional Data from the 2 Study of Its Investigational Drug Atumelnant in Cah Is Anticipated by Early 2025 - Marketscreener.com
Crinetics' Breakthrough: Phase 2 Trial Success & Novel NET Treatment Pipeline Advances | CRNX Stock News - StockTitan
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Grants 99,500 Stock Options to New Hires at $60.69, Expanding Team | CRNX Stock News - StockTitan
Lisanti Capital Growth LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (CRNX) to Release Earnings on Tuesday - Defense World
Fiera Capital Corp Sells 14,334 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Wellington Management Group LLP Reduces Stake in Crinetics Pharm - GuruFocus.com
CRNX (Crinetics Pharmaceuticals) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
(CRNX) Technical Pivots with Risk Controls - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by abrdn plc - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Crinetics Pharmace - GuruFocus.com
Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week - Yahoo Finance
Moody Aldrich Partners LLC Sells 11,053 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year HighHere's What Happened - MarketBeat
Analysts Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $68.55 - MarketBeat
State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals - Yahoo Finance
Crinetics Pharmaceuticals’ $500 Million Common Stock Offering - Global Legal Chronicle
Crinetics Pharmaceuticals outlines executive transition By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals outlines executive transition - Investing.com India
Crinetics Pharmaceuticals Inc’s results are impressive - US Post News
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 12-Month HighWhat's Next? - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 - The Bakersfield Californian
Somatostatin Receptor Type 4 Market 2034 | Key Brands -Crinetics Pharmaceuticals Inc, Strongbridge Biopharma plc - IndiaPolitics.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 4.4%Still a Buy? - MarketBeat
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):